• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Frontiers in Public Health >Multi-Criteria Decision Analysis (MCDA) Models in Health Technology Assessment of Orphan Drugsa??a Systematic Literature Review. Next Steps in Methodology Development?
【24h】

Multi-Criteria Decision Analysis (MCDA) Models in Health Technology Assessment of Orphan Drugsa??a Systematic Literature Review. Next Steps in Methodology Development?

机译：孤儿药卫生技术评估中的多标准决策分析（MCDA）模型-系统文献综述。方法学开发的下一步？

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Multi-criteria decision analysis (MCDA) is a decision-making tool that can take into account multidimensional factors and enables comparison of (medical) technologies by combining individual criteria into one overall appraisal. The MCDA approach has slowly gained traction within Health Technology Assessment (HTA) and its elements are gradually being incorporated into HTA across Europe. Several groups of scientists have proposed MCDA approaches targeted toward orphan drugs and rare diseases by including criteria specific to rare diseases. The goal of this article is to provide an overview of the current state of knowledge and latest developments in the field of MCDA in HTA for orphan drugs, to review existing models, their design characteristics, as well as to identify opportunities for further model improvement.
机译：背景：多标准决策分析（MCDA）是一种决策工具，可以考虑多维因素，并且可以通过将单个标准组合到一个整体评估中来比较（医学）技术。 MCDA方法在健康技术评估（HTA）中已逐渐受到关注，其要素逐渐被欧洲各地的HTA纳入。几组科学家提出了针对孤儿药和罕见病的MCDA方法，其中包括针对罕见病的标准。本文的目的是概述HTA中用于孤儿药物的MCDA领域的知识和最新发展概况，以审查现有模型，其设计特征，并确定进一步改进模型的机会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号